0.24
+8.64%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PuraPharm Corp
Its shares trade on HKEX under the ticker 1498.HK. It has been listed since 8 July 2015. In the fiscal year to 31 December 2025, it reported revenue of HK$336.1m and a net loss of HK$35.2m. At that date it held total assets of HK$693.8m and shareholders' equity of HK$130.5m.
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. The company employs 696 full-time employees The company went IPO on 2015-07-08. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Jul 2015
- Employees
- 696
- Website
- purapharm.com ↗
Leadership
Pay as last reported
- Mr. Yu Ling ChanExecutive Chairman of the Board, Chief Executive Officer, FounderHK$4.5m
- Dr. Hisayoshi NorimotoChief Research and Development Officer, Vice President - Production and Operations in China, Executive Director, since 2020HK$1.9m
- Mr. Gang ShiVice President, Greater China, since 2017
- Ms. Yuk Chun HoGeneral Manager - Nongs Sales and Marketing
- Ms. Qiong RuanGeneral Manager - China Sales and Marketing
- Mr. Kwun Kiu CheungFinancial Controller
- Dr. Biu Tsoi KamExecutive Director, since 2025
- Ms. Yee Wai ManExecutive Director, since 2011HK$2.1m
- Ms. Charmayne ChanCompany Secretary
- Mr. Kwok Keung LeungNon-Executive Director
- Dr. Ting On HungNon-Executive Independent Director
- Dr. Lim Kin LeungNon-Executive Independent DirectorHK$203,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 68
- Social
- 91
- Governance
- 65
- Direct emissions (scope 1)
- 577,458 t
- Energy emissions (scope 2)
- 207,278 t
- Value chain emissions (scope 3)
- 20,793,853 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PuraPharm Corp Ltd possesses several strengths that contribute to its strong market position and success:
Weaknesses
- Despite its many strengths, PuraPharm Corp Ltd also faces certain weaknesses that can hinder its growth and performance:
Opportunities
- PuraPharm Corp Ltd has several opportunities to explore and capitalize on in the pharmaceutical industry:
Threats
- PuraPharm Corp Ltd is exposed to certain threats that could potentially impact its performance and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.